What Insmed Stock’s Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
Insmed (INSM) trades about 37% below its 52-week high and still costs 25.3 times sales, against 3.3 for the S&P 500. Revenue nearly tripled over the trailing twelve months, to $1.1 billion from $0.4 billion. That premium is not being paid for the revenue on the books, but for a peak-sales estimate management has just raised, and the pieces of that estimate are not equally solid.
The Bronchiectasis Launch Is The Part Already On The Books
In the second quarter of 2026, BRINSUPRI, Insmed’s bronchiectasis drug, produced $309.2 million in its third full quarter of launch, up 49% sequentially, while ARIKAYCE, its inhalation therapy for MAC lung disease, added $116.3 million, 8% more than a year earlier. On that strength management raised full-year 2026 BRINSUPRI guidance to between $1.25 billion and $1.4 billion, from more than $1 billion. The growth is not free: the trailing-twelve-month operating margin is deeply negative at -71%, against a positive 18.5% for the S&P 500, with combined research and SG&A spending up 38% year over year to fund the launch and the pipeline.
More Than Six Billion Of The Peak Estimate Has Not Cleared Phase III
Management has raised peak revenue for the three lead programs to more than $14 billion, up 75% from its earlier estimate. More than $7 billion of that is BRINSUPRI and more than $1 billion is ARIKAYCE, both already selling. The remainder is TPIP, an inhaled treatment for pulmonary arterial hypertension and three other lung conditions, whose Phase III studies are under way in only two of the four indications. Management is explicit that the more than $6 billion figure assumes approval in all four target indications and that Insmed breaks another product’s orphan status in one of them, IPF.
Insmed Has Fallen Harder Than The Market In All Three Downturns Measured
Waiting for those results means holding through market downturns, too. The stock fell 56% in the 2020 pandemic crash while the S&P 500 fell 34%, and it fell further than the index in each of the three downturns measured. A fall of that size needs a gain far larger than itself to undo, which is the arithmetic the Trefis High Quality Portfolio is built around. Insmed ended June with about $1.2 billion in cash and marketable securities, and management says that funds the business to cash flow positivity in 2027, with no current intention to raise capital. That claim is what separates a drawdown from a dilution.
Patient Starts And Deeper Prescribing Are What Would Earn The Price
Two things would earn the price. One is whether new patient starts hold near the 7,000 a quarter management has guided to for the rest of 2026, now that the ready-and-waiting patients are gone, by the company’s own account. The other is whether prescribing keeps deepening: about 30% of the doctors prescribing BRINSUPRI have written it for at least five of their patients, up from around 20% at the end of March. Two risks sit on the other side: TPIP still has to clear Phase III in four indications, and the cash has to last until 2027 without a raise. The split between what Insmed sells today and what it might sell later is exactly what a five-factor stock scorecard is built to weigh.
Buy It Or Fear It, How Much Of It Should You Own?
Whichever way the call lands, the bigger question is how much of any single stock belongs in a portfolio at all. Strong performance is exactly how one holding quietly becomes too large a share of a portfolio. Whether that has happened in your portfolio is exactly what the Trefis Wealth team checks, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.